AnaptysBio, Inc. Stock News

AnaptysBio, Inc. - Special Call Company Participants Daniel Faga - President, CEO & Director Martin Dahl - Senior Vice President of Research John Kwon Paul Lizzul - Chief Medical Officer Conference Call Participants Joseph A. Murray, M.D Yatin Suneja - Guggenheim Securities, LLC, Research Division Joseph Thome - TD Cowen, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorp...

SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the Phase 2b trial of rosnilimab, a pathogenic T cell depleter, in rheumatoid arthritis (RA), was accepted for a late-breaking oral presentation at American College of Rheumatology (...

AnaptysBio, Inc. - Special Call Company Participants Daniel Faga - President, CEO & Director Dennis Mulroy - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Joseph Thome - TD Cowen, Research Division Andy Chen - Wolfe Research, LLC Alexander Thompson - Stifel, Nicolaus & Compan...

SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced today that its Board of Directors approved plans to explore separating its business into two independent, publicly traded companies, each poised for strong, sustainable growth. Referred to as “Royalty Management...

SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual investor event on ANB033, its CD122 antagonist, at 4:30pm ET / 1:30pm PT on Tuesday, Oct. 14.

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:   Cantor Gl...

AnaptysBio (ANAB) Q2 Revenue Jumps 103%

SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.